OncoMatch/Clinical Trials/NCT06851299
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Is NCT06851299 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including trop2-ADC and ADC +anti-angiogenic drug for metastatic triple-negative breast cancer.
Treatment: trop2-ADC · ADC +anti-angiogenic drug · ADC + PD1 monoclonal antibody +anti-angiogenic drug — This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiotherapy
receiving radiotherapy...within 4 weeks before enrollment
Cannot have received: chemotherapy
receiving...chemotherapy...within 4 weeks before enrollment
Cannot have received: endocrine therapy
receiving...endocrine therapy within 4 weeks before enrollment
Cannot have received: interventional drug clinical trial
participating in any interventional drug clinical trial
Lab requirements
Blood counts
WBC ≥3.0×10^9 / L, ANC ≥1.5×10^9 / L, PLT ≥70×10^9 / L
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min
Liver function
Total bilirubin (TBIL) ≤3× ULN; ALT/AST ≤2.5×ULN (≤5xULN in patients with liver metastases)
Cardiac function
LVEF ≥ 55%, QTcF ≤ 470 ms
adequate bone marrow reserve: a. White blood cell count (WBC) ≥3.0×10^9 / L, b. Neutrophil count (ANC) ≥1.5×10^9 / L, c. Platelet count (PLT) ≥70×10^9 / L; liver, kidney and heart function tests were basically normal (according to the normal values of the laboratories in the study center) : a. Total bilirubin (TBIL) ≤3× ULN, b. ALT/AST ≤2.5×ULN (≤5xULN in patients with liver metastases), Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min; d. LVEF ≥ 55%, e. QTcF ≤ 470 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify